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Proinflammatory cytokines and 
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Lidia Frejo  1, Alvaro Gallego-Martinez1, Teresa Requena  1, Eduardo Martin-Sanz2, Juan Carlos 
Amor-Dorado3, Andres Soto-Varela4, Sofia Santos-Perez4, Juan Manuel Espinosa-Sanchez  1,5, 
Angel Batuecas-Caletrio6, Ismael Aran7, Jesus Fraile8, Marcos Rossi-Izquierdo9 &  
Jose Antonio Lopez-Escamez  1,5,10
Epidemiological studies have found a higher prevalence of allergic symptoms and positive prick tests 
in patients with Meniere’s disease (MD); however the effect of allergenic extracts in MD has not been 
established. Thus, this study aims to determine the effect of Aspergillus and Penicillium stimulation 
in cytokine release and gene expression profile in MD. Patients with MD showed higher basal levels of 
IL-1β, IL-1RA, IL-6 and TNF-α when compared to healthy controls. We observed that IL-1β levels had 
a bimodal distribution suggesting two different subgroups of patients, with low and high basal levels 
of cytokines. Gene expression profile in peripheral blood mononuclear cells (PBMC) showed significant 
differences in patients with high and low basal levels of IL-1β. We found that both mold extracts 
triggered a significant release of TNF-α in MD patients, which were not found in controls. Moreover, 
after mold stimulation, MD patients showed a different gene expression profile in PBMC, according 
to the basal levels of IL-1β. The results indicate that a subset of MD patients have higher basal levels 
of proinflammatory cytokines and the exposure to Aspergillus and Penicillium extracts may trigger 
additional TNF-α release and contribute to exacerbate inflammation.
Meniere’s disease (MD) was first described by Prosper Menière in 1861. It is a clinical syndrome characterized 
by episodes of spontaneous vertigo lasting minutes to hours, usually associated with fluctuating, low to medium 
frequencies in sensorineural hearing loss (SNHL), tinnitus and aural fullness and it may affect one or both ears 
(bilateral MD). The diagnostic criteria for MD are based in clinical symptoms and they were reformulated jointly 
by the Classification Committee of the Bárány Society, The Japan Society for Equilibrium Research, the European 
Academy of Otology and Neurotology (EAONO), the Equilibrium Committee of the American Academy of 
Otolaryngology-Head and Neck Surgery (AAO-HNS) and the Korean Balance Society in 20151, but they do 
not consider the clinical heterogeneity observed among patients which may respond to different mechanisms of 
disease.
The prevalence of MD is about 0.5-1/1000 individuals, being most of patients considered sporadic, while 
9–10% are familial cases in European population2–4. The pathophysiology of MD is associated with the 
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accumulation of endolymph in the cochlear duct and vestibular organs5. Although a third of MD cases may have 
a dysfunction of the immune system6, the immune response in patients with MD has been seldom investigated7.
Cluster analyses using few clinical variables in a large cohort of patients with MD have identified five clinical 
subgroups in patients with unilateral and bilateral MD8,9. So, for unilateral MD, group 1 was the most frequently 
found (53%) and it was defined as sporadic MD without migraine nor autoimmune comorbidity; group 2 is 
defined by SNHL which precedes the vertigo episodes by months or years (delayed MD); group 3 includes famil-
ial cases of MD; group 4 is associated with migraine and group 5 is defined by another comorbid autoimmune 
disorder9.
Although these clinical subgroups of patients point to different potential mechanisms for the development of 
endolymphatic hydrops, the cellular and molecular bases of MD largely remain to be defined.
The link between allergy and MD was first described by Duke in 192310. He treated patients with epinephrine 
with resolution of symptoms. In 2000, Derebery conducted epidemiological studies in patients with MD finding 
that 58% of patients had a history of allergy and 41% presented a positive skin prick test11. Both, inhalatory and 
food allergens have been associated with MD12. In a non-controlled study, Topuz showed that prick test may 
induce aural symptoms such as tinnitus or aural fullness in 62% of patients and an increase of endolymphatic 
pressure measured by electrocochleography in 77% of cases13. This study suggests that certain allergens may 
induce endolymphatic hydrops. The role of allergy in the pathogenesis of MD was also evaluated by Keles et al.14 
who found significant differences in CD4, CD4/CD8, CD23 lymphocytes subpopulations and IFN-γ and IL4 
levels in patients when they were compared to controls. The prevalence of allergy was also higher in MD patients 
after evaluating IgE levels (10). Fuse et al. analyzed intracellular cytokine levels in patients with acute low-tone 
hearing loss (ALHL) and MD and they found an imbalance in the Th1/Th2 response in ALHL and an increased 
natural killer cell activity in MD15. In addition, there are other evidences supporting an altered immune response 
in MD, including the increased values of circulating immune complexes (CIC) in the serum of some patients16,17 
or the association of allelic variants in the MICA, TLR10 or NFκB genes with the progression of SNHL in MD18–20.
The aim of this study is to determine the proinflammatory cytokines profile in PBMCs and to investigate the 
effect of mold allergenic extracts in the proinflammatory response in patients with MD.
Results
Clinical features in MD patients. Patients with MD experienced attacks of vertigo with a progressive 
SNHL during the first years of the disease. Table 1 compares the clinical features of all 113 MD patients with 
uni- and bilateral MD. Patients with bilateral SNHL had a longer duration of the disease (P = 8.0 × 10−4), worse 
hearing stage (P = 0.03), higher frequency of cardiovascular risk factors (high blood pressure (P = 4 × 10−3) and 
type 2 diabetes (P = 0.024), and a higher frequency of episodes of sudden falls without spinning termed Tumarkin 
crisis (P = 6 × 10−3).
PBMC from MD patients have higher basal levels of cytokines when compared to controls. 
Basal levels of proinflammatory cytokines in the supernatant of 113 patients and 54 healthy controls were tested 
by Bead-based multiplex immunology assays. When compared to controls, MD patients had 2.8 fold higher 
expression of Interleukin-1 beta (IL-1β; P = 3.8 × 10−4); 3.8 fold higher Interleukin-1 receptor antagonist 
(IL-1RA, P = 2.74 × 10−4); 7.1 fold higher Interleukin-6 (IL-6; P = 7.83 × 10−4) and 2.6 fold more Tumor necrosis 
factor alpha (TNF-α; P = 3.5 × 10−5) (Fig. 1A).
Figure 1B shows the distribution of MD patients according to the levels IL-1β, TNF-α and IL-6. The basal levels 
of IL-1β in patients with MD showed a bimodal distribution, suggesting that two different subgroups of patients with 
MD can be distinguished according to the levels of cytokines in PBMC supernatant. So, 89 patients had low basal levels 
of IL-1β and 24 of 113 patients (21%) showed high basal levels of IL-1β (>mean + 2 standard deviation = 5.9 pg/mL; 
Supplementary Table S1). However, all control individuals had very low basal values of all measured cytokines.
Table 2 includes all patients with high basal levels of IL-1β. Twelve of them (50%) had been diagnosed as 
unilateral MD and another have 12 bilateral MD. Most of these patients were sporadic cases (22/24) and they 
were classified within the subgroup 1 (classic MD unilateral without migraine and they did not presented another 
comorbid autoimmune condition). Twenty-one of 24 (87.5%) showed elevated levels of IL-6, 19/24 (79.2%) has 
also higher levels of TNF-α and 17/24 (70.8%) presented an elevation of IL-1RA.
Mold allergenic extracts induce a higher TNF-α production in PBMCs from MD patients when 
they are compared to controls. PBMCs from all MD patients and healthy controls were stimulated with 
mold protein extracts (5μg/mL) for 16 hours and were compared to unstimulated PBMCs. When PBMCs were 
stimulated with Alternaria alternata no differences were found in IL-1β, IL-6, IL-1RA or TNFα levels between MD 
patients and healthy controls (Data not shown). However, when PBMCs were stimulated with Aspergillus (Fig. 1C) 
or Penicilium (Fig. 1D), MD patients showed higher levels TNF-α and IL-6, but no significant elevation in IL-1β.
When compared to healthy controls, PBMC of patients with high basal levels of IL-1ß had 3.2 fold higher 
expression of TNF-α in response to Aspergillus mix (p= 2.9 × 10−3), and 2.2 fold higher expression of TNF-α 
in response to Penicillium mix (p = 0.02). Patients with low levels of IL-1β presented high levels of TNF-α 
(2.7, P = 5.0 × 10−6) in response to Aspergillus and 2.7 fold higher (p = 6 × 10−6) in response to Penicillium. Of 
note, when we compared between MD patients with high and low basal of IL-1β after stimulation with either 
Aspergillus or Penicillium we found no differences in their cytokines release.
Gene expression in PBMCs from MD patients with low and high levels of IL-1ß. When we com-
pared the gene expression profiles of stimulated and non-treated PBMCs from 15 MD patients and 11 healthy 
individuals we found 1099 differentially expressed genes (DEG, >2-fold change, p < 0.02).
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In order to examine the complexities of the multivariate data we performed a principal component anal-
ysis (PCA) revealing great differences in the expression within each group (Fig. 2). Hence, because of the 
inter-individual variability, we decided to perform pairwise analysis in order to compare groups. Figure 2A shows 
a hierarchical cluster with 2 major groups: gene expression before and after stimulation. Loading plots represent 
DEGs in both, patients and controls (Fig. 2B), controls (Fig. 2C) and MD patients (Fig. 2D) before and after 
Penicillium and Aspergillus stimulation. Healthy controls showed the most significant differences in their gene 
expression profiles.
PBMC gene expression at basal levels. We compared the gene expression profile in non-treated PBMCs 
from patients with high (N = 3) and low (N = 4) basal levels of IL-1β. We found that PBMCs from patients with 
high basal levels of IL-1β have 58 DEG (p-value cutoff 0.05 and Fold Change >1.2) when they were compared 
to patients with low levels of cytokines, being the most significant gene CXCL5 with a 2.5 Fold change (adjusted 
p = 0.03). We then performed a Core analysis using IPA® software and three different networks were retrieved. 
The top ranked network had a score of 38 and involved 16/58 genes (Fig. 3). All 16 genes are involved in cellular 
function and maintenance, protein synthesis and tissue morphology. Remarkably, 21/58 genes are involved in 
immunological diseases and 32/58 in organismal Injury and abnormalities such as inflammation.
Mold-induced gene expression in PBMC. We compared the gene expression profile in Aspergillus 
or Penicillium –treated and non-treated PBMCs from 15 MD patients and 11 healthy individuals. Figure 4A 
shows a Venn diagram showing the number of DEG in controls and patients with low and high levels of IL-1β, 
after Aspergillus stimulation (Supplementary Table S2). One hundred and fifty-three genes were differentially 
expressed in the 3 groups and a top network with 29 focus molecules was retrieved, after performing a core analy-
sis (score = 55; Fig. 4B). Of note, 132 DEG were found in PBMC from patients with low levels of IL-1β retrieving a 
Variables Unilateral (n = 73) Bilateral (n = 40) P-value
Age, Mean (SD) 59 (12.3) 63 (12.8) 0.08
Gender, n (%women) 46 (63.0) 21 (52.5) 0.32
Age of Onset (SD) 48.2 (13.8) 48.4 (15.7) 0.96
Time Course (years), mean (SD) 8.3 (7.8) 14.1 (9.8) 0.0008
High Basal Levels of IL-1β 13 (19.4) 12 (29.3) 0.25
High Basal Levels of TNF-α 11 (16.4) 10 (24.4) 0.33
High Basal Levels of IL-1β and TNF-α 24 (35.8) 22 (53.7) 0.07
Family history, n (%) 19 (26.8) 10 (27.0) 1
Familial Meniere Disease, n (%) 6 (9.0) 4 (11.1) 0.74
Hearing loss at diagnosis, mean (SD) 47.5 (17.0) 54.5 (12.7) 0.06
Headache, n (%) 28 (41.8) 14 (35.9) 0.68
Migraine, n (%) 14 (20.6) 7 (17.9) 0.81
Rheumatoid history, n (%) 10 (17.5) 6 (17.6) 1
*Hearing stage, n (%)
 1 7 (9.7) 2 (5.3)
0.03
 2 25 (34.7) 6 (15.8)
 3 32 (44.4) 19 (50.0)
 4 8 (11.1) 11 (28.9)
Cardiovascular Risk factors
 High Blood Pressure, n (%) 10 (16.1) 16 (44.4) 0.004
 Dyslipemia, n (%) 9 (19.6) 12 (40.0) 0.07
 Type 2 Diabetes, n (%) 2 (3.5) 7 (20.0) 0.02
 Smoking, n (%) 10 (15.6) 7 (18.4) 0.79
 Tumarkin Crisis, n (%) 6 (9.2) 12 (32.4) 0.006
Functional level, n (%)
 1 11 (18.3) 4 (10.5)
0.24
 2 23 (38.3) 10 (26.3)
 3 12 (20.0) 12 (31.6)
 4 10 (16.7) 6 (15.8)
 5 4 (6.7) 4 (10.5)
 6 0 (0.0) 2 (5.3)
Table 1. Clinical features of patients with unilateral and bilateral Meniere disease included in the study Age, 
time course and hearing loss at diagnosis were compared by unpaired Student’s t test. Qualitative variables were 
compared by Chi-squared test. *Hearing stage, calculated for the worst ear in bilateral MD, and functional level, 
to estimate vertigo-associated disability, were measured according to the American Academy Otolaryngology 
1995 guidelines and compared by ANOVA. P values in bold were statistically significant.
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top network with 20 focus molecules (score = 35; Fig. 4C), and 75 unique DEG in PBMC from patients with high 
levels of IL-1β, retrieving a top network with 19 focus molecules (score = 41; Fig. 4D).
Next, we compared the gene expression profiles after stimulating PBMC with Penicilium extract 
(Supplementary Table S3). Figure 5 shows a Venn diagram from controls and patients with high and low levels of 
IL-1β. One hundred and forty-six DEG were common in all three groups. A top network with 25 focus molecules 
was obtained (score = 45; Fig. 5B). Remarkably, 95 unique DEG were found in PBMC from patients with low 
levels of IL-1β and 680 genes were differentially expressed in patients with high levels of IL-1β. Figure 5C (Focus 
molecules = 21; score = 41) and 5D (Focus molecules = 28; score = 37) include the networks retrieved for each 
group, respectively.
Discussion
Our study has found that basal levels of proinflammatory cytokines may be increased in some patients with MD. 
This observation is found in both patients, with uni- or bilateral MD. Furthermore, we have found that both 
Aspergillus and Penicillium extracts may induce a release of TNF-α, which is not observed in controls.
This cytokine profile may represent two subgroups of MD patients with intrinsic differences in the immune 
response or two functional states of the immune system in patients with MD. Previous studies have defined five 
clinical subgroups in patients with uni and bilateral MD9,21. Unilateral MD type 1 is the most common clinical 
variant and it includes patients without migraine, no concomitant autoimmune disease nor familial history of 
MD. Most of the patients with increased IL-1β were classified as MD type 1 (83.4%), 8.3% were MD type 3 and 
8.3% were MD type 4. None of the patients with elevated proinflammatory cytokines had an acute infection or 
another autoimmune condition that could explain this finding. So, this subset of MD patients with high basal 
levels of cytokines and negative autoantibodies may be considered as an autoinflammatory condition involv-
ing the inner ear. The field of autoinflammatory disorders has expanded from rare monogenic diseases to poly-
genic autoinflammatory diseases such Crohn disease, Behcet’s disease or sarcoidosis22,23. The characteristics of 
Figure 1. Cytokines at basal levels and after mold stimulation in PBMC. (A) All cases and controls at basal 
levels according to the levels of IL-1β. (B) Scattered-plot of MD patients according to the levels IL-1β, TNF-α 
and IL-6. Dots in green represent the patients with low levels of IL-1β (≤5.9 pg/mL) whereas dots in purple are 
the patients with high levels of IL-1β (>5.9 pg/mL) (C) All cases and controls after stimulation with Aspergillus. 
(D) All cases and controls after stimulation with Penicillium. *Significant p-values. IL-1RA, IL-1 receptor 
antagonist.
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autoinflammatory disease of the inner ear may include an innate immune response mediated by monocytes, high 
levels of IL-1β and low titers/non-specific autoantibodies24.
Moreover, our findings show that Aspergillus and Penicillium extracts trigger a significant TNF-α release in 
PBMC from patients with MD that contribute to exacerbate the inflammatory response.
The human genes in the IL-1 complex encode for three cytokines: IL-1α, IL-1β and the antagonist receptor 
IL-1RA. The severity of a given inflammation is influenced by the balance between the levels of IL-1β and that 
of IL-1 RA. In healthy individuals, IL-1 RA is readily detectable in plasma and IL-1 β levels are usually unde-
tectable25. Remarkably, IL-1RA levels were found to be much higher elevated in most patients with MD regard-
less of the levels of IL-1β. Since TLR10 is an anti-inflammatory pattern-recognition receptor able to up-regulate 
IL-1RA26, and the TLR10 allelic variant I369L rs11096955 has been associated with faster hearing loss progression 
in bilateral MD19, the activation of TLR10 could explain the increased levels of IL-1RA found in patients with 
MD. Moreover, individuals bearing I369L rs11096955 displayed increased levels of IL-1β, TNF-α and IL-6 upon 
ligation of TLR226.
This study demonstrates that allergenic extracts from Aspergillus and Penicillium induce a proinflammatory 
immune response in most patients with MD involving TNF-α, which it is not observed in controls. This mecha-
nism could initiate or exacerbate the inflammatory response in the endolymphatic sac or the spiral ligament lead-
ing to the development of endolymphatic hydrops. Previous studies also have established a relationship between 
mold extracts and proinflammatory cytokines in autoimmune inner ear disease (AIED)27. In AIED patients, iso-
lated PBMC exposed to mold increased IL-1β gene expression, and enhanced IL-6 and IL-1β secretion, that could 
act as a Pathogen-Associated Molecular Pattern (PAMP) in a subset of them. Since most of our patients with MD 
were classified as MD type 1 and did not have a comorbid autoimmune disease, and we also excluded patients 
with response to inhalatory allergens in the prick test (including Penicillium and Aspergillus), the elevation of 
TNF-α observed in patients with MD after exposure of PBMC to Penicillium and Aspergillus cannot be explained 
by another autoimmune condition or previous sensitization to other allergens.
Furthermore, it is well established that molds can cause respiratory symptoms and may worsen the course of 
bronchial asthma, which could lead to increase secretion of TNF-α, IL-6, IFN-γ or IL-1β28,29.
Our data show that Aspergillus and Penicillium trigger similar immune responses, according to the gene 
expression profile in PBMC, but few genes were specifically triggered by Penicillium in patients with high basal 
levels of IL-1β such as TNFRSF6B, CXCR4 or CD14 (up-regulated) and FCGR3B or HLA-DRB4 (down-regulated). 
In addition, some genes were also specifically expressed in patients with low basal levels of IL-1β such as VEGFA, 
Patient Gender Ear
Age of 
Onset
Duration of 
Disease (y)
Familial 
MD Migraine
Hearing 
stage
High blood 
pressure
Response to 
oral steroids
MD 
Subgroup
High basal 
IL-6
High basal 
TNF-α
1 Man Right 51 2 No No 3 No ? 1 Yes Yes
2 Woman Right 39 3 No No 1 No ? 1 Yes Yes
3 Man Left 42 1 Yes No 1 No Yes 3 Yes Yes
4 Man Left 60 1 No No 3 No ? 1 Yes Yes
5 Woman Left 51 17 No No 3 Yes ? 1 Yes Yes
6 Woman Right 51 12 No Yes 2 No ? 4 Yes Yes
7 Woman Right 79 5 No No 2 No Yes 1 Yes Yes
8 Man Bilateral 31 39 No No 4 ? ? 1 Yes Yes
9 Man Bilateral 52 13 No No 1 Yes ? 1 Yes No
10 Man Bilateral 56 12 No No 2 ? ? 1 No No
11 Woman Bilateral 45 11 No No 2 No ? 1 Yes No
12 Woman Left 50 9 No Yes 1 No ? 4 No Yes
13 Woman Bilateral 48 10 No No 3 No ? 1 Yes Yes
14 Woman Bilateral 53 14 No No 2 No ? 1 Yes Yes
15 Man Bilateral 37 11 No No 4 No No 1 Yes Yes
16 Man Bilateral 50 24 No No 3 Yes ? 1 Yes Yes
17 Man Bilateral 30 29 No No 4 No ? 1 Yes Yes
18 Man Bilateral 59 8 No No 4 No ? 1 Yes Yes
19 Man Bilateral 73 10 No No 4 Yes Yes 1 Yes Yes
20 Woman Left 52 10 No No 3 No ? 1 No No
21 Woman Right 43 21 Yes No 3 No ? 3 Yes Yes
22 Woman Left 45 11 No No 3 No ? 1 Yes Yes
23 Man Right 50 14 No No 3 No ? 1 Yes No
24 Man Bilateral 28 24 No No 3 No Yes 1 Yes Yes
Table 2. Clinical features of 24 patients with MD and elevated proinflammatory cytokines at basal levels. None 
of the patients have another autoinmune disorder. MD subgroup: 1, unilateral or bilateral disease without 
migraine, familial history of MD or another comorbid autoinmune condition; 3, familial MD; 4, MD with 
migraine.
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LAIR2 or CD82 (up-regulated) and CX3CR1 or SNAP23 (down-regulated). We found that IL6 and CXCL5 genes 
were key mediators in molds-trigger response in all controls and patients with MD, regardless of the IL-1β levels.
We also observed that only 58 genes were differentially expressed in MD patients with high basal levels of 
IL-1β, after stimulation with either Aspergillus or Penicillium. This gene expression profile was not found neither 
in controls or patients with low levels of IL-1β, supporting the hypothesis that this abnormal immune response 
with high levels of IL-1β may facilitate the identification of a subgroup of MD patients with elevated proinflam-
matory cytokines and a specific mold-induced gene expression profile. A major part of the genes retrieved from 
our data revealed networks associated to cellular movement, immune cell trafficking, cell morphology and molec-
ular transport. Thus, the probable pathways involved within these networks would be Granulocyte/Agranulocyte 
Adhesion and Diapedesis, Communication between Innate and Adaptative Immune cells and Role of Cytokines 
in mediating communication between immune cells.
Our results add new evidence to support that MD is a heterogeneous disorder and the levels of proinflamma-
tory cytokines and the differences in the immune response to certain pathogens, including molds, may explain 
that some patients respond to drugs with antihistaminic effects, such as betahistine, but most patients do not 
show a response different from placebo30. Moreover, since patients using immunotherapy have reported an 
improvement of the duration and frequency of the vertigo episodes compared to controls11, the assessment of 
allergic response in patients with MD, and the use of antihistaminic or immunotherapy as part of the treatment 
plan to control vertigo attacks should be considered.
The major limitation of our study is that the number of investigated patients was low (N = 113), and further 
patients will need to be tested to validate our findings. However, we found that 21% of MD patients had higher 
basal levels of IL-1β. Pilot clinical trials will determine if these individuals may benefit from target therapies to 
block IL-1β such as anakinra (recombinant anti-IL1RA) and canakinumab (anti-IL1β monoclonal antibody), as 
it has been shown in AIED31.
Figure 2. Gene expression in PBMC. (A) Dendrogram showing hierarchical clustering of patients, according 
to the gene expression in PBMCs. (B) Three dimensional loading plot showing principal component analysis 
(PCA) eigenvectors using all datasets. (C) Loading plots in controls before and after stimulation. (D) Loading 
plots in MD patients before and after stimulation.
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Conclusions
1.  A subset of patients with Meniere disease has elevated levels of proinflamatory cytokines and they may 
have an autoinflammatory inner ear disease.
2.  Aspergillus and Penicillium trigger the release of TNF-α in MD patients and this could initiate or exacer-
bate the inflammatory response in the inner ear.
Materials and Methods
Human subjects. This study included a total of 113 patients with definite MD according to the diagnostic 
criteria of the Barany Society1 and 54 healthy controls. All patients had, at least, 3 years of follow-up since the 
onset of the disease.
Individuals over 18 years old were recruited from 9 otoneurology clinics from January 2015 to December 
2016. Control subjects matching sex and age with MD patients were selected (mean age 54 ± 12, 55.3% women). 
All participants underwent allergic screening by dermal prick test (ALK Abello, A/S, Hørsholm, Denmark) to 
respiratory allergens. All individuals showed negative response to the prick test and those under steroid therapy 
during the last 3 months were excluded from the study.
All patients and healthy individuals gave their informed consent for the study. Blood samples were collected 
during the quiescent phase of the disease. The study was carried out according to the principles of the Declaration 
of Helsinki revised in 201332 for investigation with humans. The Almeria Ethical Review board for clinical 
research approved the research protocol PI13-01242.
PBMC culture and stimulation. Peripheral blood mononuclear cells (PBMC) were isolated and cultured in 
RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Biowest, Nuaillé, France) as previously described33. 
Cells were plated at 1 × 106 cells/mL in 12-well plates. In some experiments, fungus extracts were added (2 differ-
ent Allergenic Extract-Mix fungus containing, in one case, 4 equal parts of Mix Aspergillus (oryzae, repens, niger 
and terreus; code#1034497) and in the other case, 4 equal parts of Mix Penicillium (brevicompactum, expansum, 
notatum and roqueforti; code#1034760)). Additionally, Alternaria alternata was used in some experiments (ALK 
Abelló A/S, Hørsholm, Denmark). Each combination was dialyzed to remove phenol by using Tube-o-dialyzer 
(VWR Intranational, Radnor, PA, USA) against deionized distilled water. Fungus protein concentration was ana-
lyzed by Bradford dye-binding method protein assay (Bio-Rad Laboratories, Hercules, CA, USA)34. One × 106 
Figure 3. Top Network from MD patients PBMCs at basal levels. Network retrieved after comparing by 
pairwise analysis gene expression data from MD patients PBMCs with high and low basal levels of IL-1β. Genes 
in red were up-regulated, while genes in green were down-regulated.
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PBMC per mL was stimulated with 5 μg/mL of each dialyzed mix fungus. PBMC were incubated during 16 h at 
37 °C in 7% CO2 and compared with cultured, unstimulated PBMC. The optimal concentrations of these mixtures 
were previously identified by culturing PBMC with increasing concentrations (5, 10, 20 μg/mL) of these reagents 
to identify the best concentration (mold mix: 5 μg/mL) that could be used without distressing cell viability (viabil-
ity >80%). At the end of all incubations, PBMC were centrifuged, RNA and proteins harvested and supernatants 
were collected and stored at −20 °C.
Cytokine Measurement. Conditioned supernatants were collected and stored at −20 °C until a sufficient 
number of samples were acquired. Frozen samples were thawed immediately prior to analysis and none of the 
samples underwent repetitive freeze-thawing cycles prior to analysis. IL-1β, IL-6, IL-1RA and TNFα levels in 
conditioned supernatant were quantified simultaneously with a commercially available Multiplex Bead-Based Kit 
(EMD Millipore, Billerica, MA, USA), in accordance with the kit-specific protocols provided by Millipore, using a 
Luminex 200 (Luminex Corp., Austin, TX, USA) and read with Luminex × PONENT 3.1 software.
The minimum detection limit for the assay was 0.14 pg/mL and the maximum 10000 pg/mL. Samples with 
readings below or above these levels were assigned values of 0 pg/mL for the minimum value or 10000 pg/mL for 
the maximum value. The percentages of samples with levels below 0.14 pg/mL (detection limit for unstimulated 
samples) were: IL-1β 0.08%, IL-1RA 0.03%, IL-6 0.006% and TNF-α 0%. The percentages of samples with levels 
above 10000 pg/mL (detection limit for samples stimulated with Aspergillus) were: IL-1β 0.006%, IL-1RA 0%, 
Figure 4. Differentially expressed genes after Aspergillus stimulation. (A) Venn diagram showing the number 
of differentially expressed genes in controls, MD patients with low basal levels of IL-1β and patients with high 
basal levels of IL-1β. (B) Network obtained after taking common genes to all groups. (C) Network retrieved 
in MD patients with low basal levels of IL-1β unique DEG. (D) Network obtained after taking MD patients 
with high basal levels of IL-1β unique DEG. Genes in red were up-regulated, while genes in green were down-
regulated.
www.nature.com/scientificreports/
9Scientific RepoRts |  (2018) 8:5974  | DOI:10.1038/s41598-018-23911-4
IL-6 0.06% and TNF-α 0.047%; and for samples stimulated with Penicillium were: IL-1β 0.012%, IL-1RA 0%, IL-6 
0.05% and TNF-α 0.6%.
We measured the cytokines in duplicate and determined the reliability of the measurements by calculating 
the Intraclass Correlation Coefficient (ICC). ICC for each cytokine was greater than 80% in samples stimulated 
with Mix Apergillus: IL-1β 97.8%, IL-1RA 98.2%, IL-6 81% and TNF-α 94%; and samples stimulated with Mix 
Penicillium: IL-1β 94.9%, IL-1RA 90.2%, IL-6 84.5% and TNF-α 91.7%. In addition, we had two quality controls 
for each cytokine (provided by the manufacturer with the kit), run in duplicate, which were within the expected 
range with coefficients of variation less than 8%.
IL-1β, IL-6 ELISA. IL-1β and IL-6 levels were quantified, in 30 conditioned supernatant samples, using a sand-
wich ELISA (R&D Systems, Minneapolis, MN, USA) as described by the manufacturer’s procedure. All samples 
were run in duplicate. The minimum detection limit for the assays was 0.17 pg/mL and the maximum 450 pg/mL. 
Samples with readings below or above these levels were assigned values of 0 pg/mL for the minimum value. No sam-
ple was above the maximum value. Correlation between ELISA and Multiplex Bead-Based assay was greater than 
85% for both cytokines.
RNA extraction. RNA was isolated using the High Pure RNA isolation Kit (Hoffmann-La Roche, Basel, 
Switzerland) according to the manufacturer’s protocol. RNA concentration was measured on a Nanodrop 
Figure 5. Differential expressed genes after Penicillium stimulation. (A) Venn diagram showing the number 
of differentially expressed genes in controls, MD patients with low basal levels of IL-1β and patients with high 
basal levels of IL-1β. (B) Network obtained after taking common genes to all groups. (C) Network obtained after 
taking MD patients with low basal levels of IL-1β unique DEG. (D) Network obtained after taking MD patients 
with high basal levels of IL-1β unique DEG. Genes in red were up-regulated, while genes in green were down-
regulated.
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(NanoDrop Technologies Inc.,Wilmington, DE, USA). RNA quality was checked using Agilent 2100 Bioanalyzer 
(Agilent Technologies, Waldbronn, Germany).
Expression array. HumanHT-12 v4 Expression BeadChip (Illumina Inc., San Diego, CA, USA) provides 
genome-wide transcriptional coverage of more than 47,000 probes, including well-characterized genes, gene can-
didates, and splice variants. In short biotin-labeled
cRNA samples were prepared as described by manufacturer’s protocol using 500ng of purified total RNA 
as a template for the reaction and then, processed with the high resolution scanner iScan (Illumina Inc., San 
Diego, CA, USA). Probe intensity data were analyzed using Illumina’s GenomeStudio software (Gene Expression 
Module). In order to determine gene average expression levels a median normalization was used according to 
control probe profiles.
Statistical analysis. A descriptive statistical analysis for clinical data was performed using SPSS software 
v.22 (SPSS Inc, Chicago, IL, USA). Data are shown as means ± standard deviation (SD). Quantitative variables 
were compared using Student’s unpaired T-test. Qualitative variables were compared using crosstabs and Fisher’s 
exact test. Nominal p-values < 0.05 were considered statistically significant.
The R statistical software version 3.2.3 and RStudio were used for all analyses in gene expression data 
(www.r-project.org). Limma R package from Bioconductor was used for expression data analysis, normalization 
and differential expression analysis. We used a pairwise t-statistic approach for each comparison and followed 
Benjamini and Hochberg’s correction in order to control the false discovery rate. An adjusted P value cutoff of 
0.02 was considered for differentially expressed genes (DEG).
Signaling pathway analysis was performed using Ingenuity Pathways Analysis software (IPA®, Qiagen, Venlo, 
Netherlands, http://www.ingenuity.com/products/ipa). Core analysis tool was executed using DEG.
A PCA was performed for gene expression data using DEG (dots = genes; lines with arrows =  MD patients 
and controls before and after stimulation; 3-axis = PC1, PC2 and PC3). Loading plots were generated to visualize 
the relationship between groups. Using this method, the basal levels and after stimulation were separated using 
PC1, PC2, and PC3, according to DEG. IPA network scores are derived from p-values. If are n genes in the net-
work and f of them are Focus Genes. The p-value  is the probability of finding f or more Focus Genes in a set of n 
genes randomly selected from the Global Molecular Network database in IPA. It is calculated using Fisher’s exact 
test as described in IPA user’s instructions. Therefore, the p-score is defined as: p-score =  −log10 (p-value).
We compared the gene expression profile of stimulated and non-stimulated PBMCs using the web-based soft-
ware GeneSifter performing a 2-way ANOVA, in order to define a significant effect of Penicillium and Aspergillus 
stimulation, or any difference between patients with low and high basal levels of IL-1β (P < 0.02; threshold 2-fold 
change).
Data availability. The datasets generated in this study are available from the corresponding author on rea-
sonable request and can be obtained from Gene Expression Omnibus with the accession number GSE109558.
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